The Main Rhinovirus Respiratory Tract Adhesion Site (ICAM-1) is Upregulated in Smokers and Patients with Chronic Airflow Limitation (CAL)
Overview
Authors
Affiliations
Background: ICAM-1 is a major receptor for ~60% of human rhinoviruses, and non-typeable Haemophilus influenzae, two major pathogens in COPD. Increased cell-surface expression of ICAM-1 in response to tobacco smoke exposure has been suggested. We have investigated epithelial ICAM-1 expression in both the large and small airways, and lung parenchyma in smoking-related chronic airflow limitation (CAL) patients.
Methods: We evaluated epithelial ICAM-1 expression in resected lung tissue: 8 smokers with normal spirometry (NLFS); 29 CAL patients (10 small-airway disease; 9 COPD-smokers; 10 COPD ex-smokers); Controls (NC): 15 normal airway/lung tissues. Immunostaining with anti-ICAM-1 monoclonal antibody was quantified with computerized image analysis. The percent and type of cells expressing ICAM-1 in large and small airway epithelium and parenchyma were enumerated, plus percentage of epithelial goblet and submucosal glands positive for ICAM- 1.
Results: A major increase in ICAM-1 expression in epithelial cells was found in both large (p < 0.006) and small airways (p < 0.004) of CAL subjects compared to NC, with NLFS being intermediate. In the CAL group, both basal and luminal areas stained heavily for ICAM-1, so did goblet cells and sub-mucosal glands, however in either NC or NLFS subjects, only epithelial cell luminal surfaces stained. ICAM-1 expression on alveolar pneumocytes (mainly type II) was slightly increased in CAL and NLFS (p < 0.01). Pack-years of smoking correlated with ICAM-1 expression (r = 0.49; p < 0.03).
Conclusion: Airway ICAM-1 expression is markedly upregulated in CAL group, which could be crucial in rhinoviral and NTHi infections. The parenchymal ICAM-1 is affected by smoking, with no further enhancement in CAL subjects.
Shahzad A, Lu W, Dey S, Bhattarai P, Gaikwad A, Jaffar J J Clin Med. 2024; 13(7).
PMID: 38610892 PMC: 11012432. DOI: 10.3390/jcm13072126.
Can the ADO Index Be Used as a Predictor of Mortality from COVID-19 in Patients with COPD?.
Ertan Yazar E, Gunluoglu G, Arpinar Yigitbas B, Calikoglu M, Gulbas G, Demirci N Int J Chron Obstruct Pulmon Dis. 2024; 19:851-858.
PMID: 38596202 PMC: 11001538. DOI: 10.2147/COPD.S440099.
Guillien A, Niespodziana K, Mauclin M, Boudier A, Varraso R, Leynaert B Front Immunol. 2024; 15:1355214.
PMID: 38500884 PMC: 10945029. DOI: 10.3389/fimmu.2024.1355214.
Bacterial Vaccinations in Patients with Chronic Obstructive Pulmonary Disease.
Paroczai D, Burian K, Bikov A Vaccines (Basel). 2024; 12(2).
PMID: 38400196 PMC: 10893474. DOI: 10.3390/vaccines12020213.
Circulating biomarkers of airflow limitation across the life span.
Zhai J, Voraphani N, Imboden M, Keidel D, Liu C, Stern D J Allergy Clin Immunol. 2024; 153(6):1692-1703.
PMID: 38253260 PMC: 11162345. DOI: 10.1016/j.jaci.2023.12.026.